Cerenkov Radiation Induced Photodynamic Therapy Using Chlorin E6-Loaded Hollow Mesoporous Silica Nanoparticles
Overview
Biotechnology
Authors
Affiliations
Traditional photodynamic therapy (PDT) requires external light to activate photosensitizers for therapeutic purposes. However, the limited tissue penetration of light is still a major challenge for this method. To overcome this limitation, we report an optimized system that uses Cerenkov radiation for PDT by using radionuclides to activate a well-known photosensitizer (chlorin e6, Ce6). By taking advantage of hollow mesoporous silica nanoparticles (HMSNs) that can intrinsically radiolabel an oxophilic zirconium-89 (Zr, t = 78.4 h) radionuclide, as well as possess great drug loading capacity, Ce6 can be activated by Cerenkov radiation from Zr in the same nanoconstruct. In vitro cell viability experiments demonstrated dose-dependent cell deconstruction as a function of the concentration of Ce6 and Zr. In vivo studies show inhibition of tumor growth when mice were subcutaneously injected with [Zr]HMSN-Ce6, and histological analysis of the tumor section showed damage to tumor tissues, implying that reactive oxygen species mediated the destruction. This study offers a way to use an internal radiation source to achieve deep-seated tumor therapy without using any external light source for future applications.
Radionuclide-labelled nanoparticles for cancer combination therapy: a review.
Sun N, Wang T, Zhang S J Nanobiotechnology. 2024; 22(1):728.
PMID: 39578828 PMC: 11585169. DOI: 10.1186/s12951-024-03020-3.
Zhang X, Guo J, Zhou Z, Feng K, Liu H, Ruan Y Chem Biomed Imaging. 2024; 2(4):275-282.
PMID: 39473776 PMC: 11504187. DOI: 10.1021/cbmi.3c00098.
Narayana S, Gowda B, Hani U, Shimu S, Paul K, Das A J Nanobiotechnology. 2024; 22(1):427.
PMID: 39030546 PMC: 11264527. DOI: 10.1186/s12951-024-02701-3.
New Opportunities and Old Challenges in the Clinical translation of Nanotheranostics.
Gawne P, Ferreira M, Papaluca M, Grimm J, Decuzzi P Nat Rev Mater. 2024; 8(12):783-798.
PMID: 39022623 PMC: 11251001. DOI: 10.1038/s41578-023-00581-x.
Hubinger L, Wetzig K, Runge R, Hartmann H, Tillner F, Tietze K Pharmaceutics. 2024; 16(4).
PMID: 38675195 PMC: 11054706. DOI: 10.3390/pharmaceutics16040534.